DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider
of outsourced development services to the pharmaceutical, biotechnology
and medical device industries, today announced that all resolutions
recommended by the Board at the Extraordinary General Meeting ("EGM") of
the Company, held on 17th December 2012, were duly
passed by shareholders. These resolutions, relating to the proposed
conversion to a direct NASDAQ listing for ICON Shares, were set out in
the Notice of the EGM sent to shareholders on 16th November
2012 and are available on the ICON
plc website.
Forms of Proxy were received before the meeting, appointing proxies and
giving them the following voting instructions:
|
|
|
|
|
TOTAL NUMBER
OF PROXIES
|
|
|
|
VOTE FOR
|
|
|
|
VOTE
AGAINST
|
|
|
|
VOTE
WITHHELD
|
|
|
|
|
Resolution Number
|
|
|
|
|
|
|
|
Number of Votes
|
|
|
|
Number of Votes
|
|
|
|
Number of Votes
|
|
|
|
|
1
|
|
|
|
53,406,101
|
|
|
|
53,341,438
|
|
|
|
246
|
|
|
|
64,417
|
|
|
|
|
2**
|
|
|
|
53,406,101
|
|
|
|
53,329,851
|
|
|
|
3,081
|
|
|
|
73,169
|
|
|
|
|
3**
|
|
|
|
53,406,101
|
|
|
|
53,009,922
|
|
|
|
6,211
|
|
|
|
389,968
|
|
|
|
** Special Resolution. All resolutions are ordinary resolutions unless
otherwise stated.
Consequently, the date of delisting from the Irish Stock Exchange is
expected to be 30th January 2013 and the expected date of the
termination of the current ADR programme is 1st February
2013. The direct trading of ICON Shares on NASDAQ is expected to
commence on 4th February 2013.
The information contained in this release is as of 18th
December 2012. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to ICON
and its business can be found in ICON's
Annual Report for the fiscal year ended December 31, 2011 and in the
forms filed with the US
Securities and Exchange Commission, including the Forms 20-F, F-1,
S-8 and F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
About ICON plc:
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 82 locations in 40 countries and
has approximately 9,430 employees. Further information is available at www.iconplc.com.
SOURCE: ICON plc
ICON/ICLR-F
ICON plc
Investor Relations
1-888-381-7923
or
Brendan
Brennan
Chief Financial Officer
+ 353 —1-291-2000
or
Sam
Farthing
VP Investor Relations
+ 353 —1-291-2000
Source: ICON
News Provided by Acquire Media
